Skip to main content

Table 2 Unadjusted response rates for LDA or remission at 1 year in all patients and by subgroup in the trimmed and stratified-matched populations

From: Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

 

Trimmed population

Stratified-matched population

Rituximab

Anti-TNF agent

Rituximab

Anti-TNF

(n = 265)

(n = 737)

(n = 205)

(n = 205)

Patients, number

LDA or remission

Patients, number

LDA or remission

Patients, number

LDA or remission

Patients, number

LDA or remission

Overall, n (%)*

265

91 (34.3)

737

248 (33.7)

205

75 (36.6)

205

59 (28.8)

 Remained on drug

165

71 (43.0)

379

196 (51.7)

127

59 (46.5)

94

45 (47.9)

 Not retreated with rituximab or discontinued anti-TNF

57

20 (35.1)

141

52 (36.9)

47

16 (34.0)

40

14 (35.0)

 Switched

43

N/A

217

N/A

31

N/A

71

N/A

  1. * P = 0.82 for the trimmed population; P = 0.09 for the stratified-matched population. Anti-TNF anti–tumor necrosis factor, LDA low disease activity, N/A not available